https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/accounts-payable https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/accounts-receivable https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/accounts-receivable-net https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/accretion-expense https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/accrued-liabilities-current https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/accrued-professional-fees-current https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/accumulated-depreciation https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/acquired-deferred-tax-liabilities-noncurrent https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/acquisition-bargain-purchase-gain-recognized-amount https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/acquisition-contingent-consideration-arrangements-change-in-amount-of-contingent-consideration-asset https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/acquisition-contingent-consideration-arrangements-change-in-amount-of-contingent-consideration-liability https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/activist-13d-13g-form-sc-13d https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/activist-13d-13g-form-sc-13g https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/additional-paid-in-capital-common-stock https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/allocated-share-based-compensation-expense https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/amended-reports-10-k https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/amortization https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/amortization-of-debt-discount-premium https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/amortization-of-financing-costs-and-discounts https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/aoci https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/area-of-real-estate-property https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/asset-impairment-charges https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/assets-held-for-sale-not-part-of-disposal-group-current https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/available-for-sale-amortized-cost https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/available-for-sale-current https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/available-for-sale-debt-maturities-within-one-year-amortized-cost https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/available-for-sale-debt-maturities-within-one-year-fair-value https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/available-for-sale-debt-securities https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/available-for-sale-fair-value-disclosure https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/available-for-sale-gross-unrealized-gain https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/available-for-sale-gross-unrealized-losses https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/available-for-sale-securities https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/basic-shares https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/buybacks-form-sc-to-i https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/buybacks-share-repurchases https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/buybacks-shares-repurchased-value https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/capital-expenditures https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/capital-lease-obligations https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/capital-lease-obligations-incurred https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/capital-leased-assets-gross https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/capital-leases-future-minimum-payments-due https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/capital-leases-future-minimum-payments-due-current https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/capital-leases-future-minimum-payments-due-in-five-years https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/capital-leases-future-minimum-payments-due-in-four-years https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/capital-leases-future-minimum-payments-due-in-three-years https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/capital-leases-future-minimum-payments-due-in-two-years https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/capital-leases-future-minimum-payments-due-thereafter https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/capital-leases-future-minimum-payments-interest-included-in-payments https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/capital-leases-future-minimum-payments-present-value-of-net-minimum-payments https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/capital-leases-future-minimum-payments-remainder-of-fiscal-year https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/capital-leases-lessee-balance-sheet-assets-by-major-class-accumulated-deprecation https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/capitalized-computer-software-net https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/cash-acquired-from-acquisition https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/cash-and-equivalents https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/cash-flow-breakdown https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/cash-provided-by-used-in-investing-activities-discontinued-operations https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/cash-provided-by-used-in-operating-activities-discontinued-operations https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/certificates-of-deposit-at-carrying-value https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/class-of-warrant-or-right-exercise-price-of-warrants-or-rights https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/class-of-warrant-or-right-number-of-securities-called-by-warrants-or-rights https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/common-stock-capital-shares-reserved-for-future-issuance https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/common-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/common-stock-value https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/comprehensive-income https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/concept-stock-issued-tag-2 https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/contracts-revenue https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/conversion-of-stock-amount-converted https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/convertible-notes-payable-current https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/cost-of-goods-sold https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/cover-page-shares-outstanding https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/current-assets https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/current-federal-tax-expense-benefit https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/current-foreign-tax-expense-benefit https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/current-liabilities https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/debt-conversion-converted-instrument-amount https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/debt-increase-accrued-interest https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/debt-issued https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/debt-maturing-in-next-twelve-months https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/debt-maturing-in-year-four https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/debt-maturing-in-year-three https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/debt-maturing-in-year-two https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/debt-repaid https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/debt-unamortized-discount https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/deferred-income-tax-expense-benefit https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/deferred-income-tax-liabilities https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/deferred-income-tax-liabilities-net https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/deferred-income-taxes-and-tax-credits https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/deferred-rent-credit-noncurrent https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/deferred-revenue https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/deferred-revenue-noncurrent https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/deferred-tax-assets-deferred-income https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/deferred-tax-assets-gross https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/deferred-tax-assets-gross-current https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/deferred-tax-assets-gross-noncurrent https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/deferred-tax-assets-in-process-research-and-development https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/deferred-tax-assets-liabilities-net https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/deferred-tax-assets-liabilities-net-current https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/deferred-tax-assets-operating-loss-carryforwards https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/deferred-tax-assets-operating-loss-carryforwards-domestic https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/deferred-tax-assets-operating-loss-carryforwards-foreign https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/deferred-tax-assets-other https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/deferred-tax-assets-property-plant-and-equipment https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/deferred-tax-assets-stock-compensation https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/deferred-tax-assets-tax-credit-carryforwards-alternative-minimum-tax https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/deferred-tax-assets-tax-credit-carryforwards-research https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/deferred-tax-assets-tax-deferred-expense-reserves-and-accruals-accrued-liabilities https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/deferred-tax-assets-tax-deferred-expense-reserves-and-accruals-deferred-rent https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/deferred-tax-liabilities https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/deferred-tax-liabilities-current https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/deferred-tax-liabilities-deferred-expense-capitalized-research-and-development-costs https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/deferred-tax-liabilities-goodwill-and-intangible-assets-intangible-assets https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/deferred-tax-liabilities-gross-noncurrent https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/deferred-tax-liabilities-noncurrent https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/defined-contribution-plan-employer-discretionary-contribution-amount https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/depreciation-and-amortization https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/depreciation-and-amortization-expense https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/depreciation-nonproduction https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/diluted-shares https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/discontinued-operation-gain-loss-on-disposal-of-discontinued-operation-net-of-tax https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/discontinued-operation-income-loss-from-discontinued-operation-during-phase-out-period-net-of-tax https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/dividends-preferred-stock https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/earnings-per-share-basic-and-diluted https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/effective-tax-rate https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/employee-related-liabilities-current https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/exchange-rate-effect-on-cash https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/extinguishment-of-debt-amount https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/extraordinary-item-net-of-tax https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/fair-value-adjustment-of-warrants https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/fair-value-assumptions-expected-volatility-rate https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/fair-value-assumptions-risk-free-interest-rate https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/fair-value-of-assets-acquired https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/federal-income-tax-expense-benefit https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/financing-cash-flow https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/finite-lived-intangible-assets-accumulated-amortization https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/finite-lived-intangible-assets-amortization-expense-after-year-five https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/finite-lived-intangible-assets-amortization-expense-next-twelve-months https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/finite-lived-intangible-assets-amortization-expense-remainder-of-fiscal-year https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/finite-lived-intangible-assets-amortization-expense-year-five https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/finite-lived-intangible-assets-amortization-expense-year-four https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/finite-lived-intangible-assets-amortization-expense-year-three https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/finite-lived-intangible-assets-amortization-expense-year-two https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/finite-lived-intangible-assets-gross https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/finite-lived-intangible-assets-net https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/finitelived-intangible-assets-acquired https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/foreign-currency-transaction-gain-loss-before-tax https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/foreign-currency-transaction-gain-loss-unrealized https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/foreign-income-tax-expense-benefit https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/foreign-pretax-income https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/form-d-other https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/future-minimum-sublease-rentals-sale-leaseback-transactions https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/gain-loss-on-disposition-of-assets https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/gain-loss-on-disposition-of-intangible-assets https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/gain-loss-on-sale-of-business https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/gain-loss-on-sale-of-leased-assets-net-operating-leases https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/gain-loss-on-sale-of-property-plant-equipment https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/gain-loss-related-to-litigation-settlement https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/gains-losses-on-extinguishment-of-debt https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/general-and-administrative-expense https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/goodwill https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/goodwill-acquired https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/goodwill-impaired-accumulated-impairment-loss https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/goodwill-written-off-related-to-sale-of-business-unit https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/impairment-of-intangible-assets-finitelived https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/impairment-of-intangible-assets-indefinitelived-excluding-goodwill https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/impairment-of-long-lived-assets-to-be-disposed-of https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/income-loss-from https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/income-loss-from-discontinued-operations-net-of-tax https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/income-loss-from-discontinued-operations-net-of-tax-attributable-to-reporting-entity https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/income-loss-from-discontinued-operations-net-of-tax-per-basic-and-diluted-share https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/income-loss-from-per-basic-and-diluted-share https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/income-tax https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/income-tax-at-federal-statutory-rate https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/income-taxes-paid https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/increase-decrease-in-accounts-payable https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/increase-decrease-in-accounts-payable-and-accrued-liabilities https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/increase-decrease-in-accounts-receivable https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/increase-decrease-in-accrued-liabilities https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/increase-decrease-in-deferred-revenue https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/increase-decrease-in-other-noncurrent-assets https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/increase-decrease-in-other-noncurrent-liabilities https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/increase-decrease-in-prepaid-deferred-expense-and-other-assets https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/increase-decrease-in-receivables https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/increase-decrease-in-restricted-cash https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/insider-transactions-other https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/insider-transactions-stock-options https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/insider-transactions-stock-units https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/insider-transactions-warrants https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/intangible-assets-net-excluding-goodwill https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/interest-expense https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/interest-income-expense-net https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/interest-paid https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/interest-paid-net https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/interest-payable-current https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/investing-cash-flow https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/investment-income-interest https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/late-filing-notices-nt-10-k https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/lease-and-rental-expense https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/lease-incentive-payable-current https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/liabilities-assumed https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/liabilities-of-disposal-group-including-discontinued-operation https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/liability-for-uncertain-tax-positions-current https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/license-and-services-revenue https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/licenses-revenue https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/loans-payable-current https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/long-term-debt https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/long-term-loans-payable https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/net-cash-from https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/net-cash-from-financing-activities https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/net-cash-from-investing-activities https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/net-cash-from-operating-activities https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/net-change-in-cash https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/net-income https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/noncash-merger-related-costs https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/noncash-or-part-noncash-acquisition-fixed-assets-acquired https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/notes-payable-current https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/number-of-credit-risk-derivatives-held https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/number-of-operating-segments https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/oci-foreign-currency-transaction-and-translation-adjustment-net-of-tax https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/oci-foreign-currency-translation-adjustment-tax https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/oci-unrealized-holding-gain-loss-on-securities-arising-net-of-tax https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/operating-cash-flow https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/operating-expenses https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/operating-income https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/operating-lease-payments-due https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/operating-lease-payments-due-current https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/operating-lease-payments-due-future-minimum-sublease-rentals https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/operating-lease-payments-due-in-five-years https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/operating-lease-payments-due-in-four-years https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/operating-lease-payments-due-in-three-years https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/operating-lease-payments-due-in-two-years https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/operating-lease-payments-due-thereafter https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/operating-leases-future-minimum-payments-remainder-of-fiscal-year https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/operating-leases-rent-expense-net https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/operating-loss-carryforwards https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/other-accrued-liabilities-current https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/other-assets-held-for-sale-current https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/other-current-assets https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/other-current-liabilities https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/other-income https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/other-noncash-income-expense https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/other-noncurrent-assets https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/other-noncurrent-liabilities https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/other-nonoperating-income-expense https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/other-prepaid-expense-current https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/other-significant-noncash-transaction-value-of-consideration-given https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/paid-in-capital-share-based-compensation-stock-options-requisite-service-period-recognition https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/paid-in-capital-stock-compensation https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/paid-in-capital-warrant-issued https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/participating-securities-distributed-and-undistributed-earnings https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/payments-for-restructuring https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/payments-of-debt-issuance-costs https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/payments-of-financing-costs https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/payments-to-acquire-businesses-gross https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/payments-to-acquire-in-process-research-and-development https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/payments-to-acquire-short-term-investments https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/preferred-shares-facts https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/preferred-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/preferred-stock-shares-authorized https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/preferred-stock-shares-issued https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/preferred-stock-shares-outstanding https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/prepaid-expense-and-other-assets-current https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/prepaid-insurance https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/pretax-income https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/pretax-income-domestic https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/pretax-income-minority-interest-and-income-loss-from-equity-method-investments https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/proceeds-from-convertible-debt https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/proceeds-from-debt-net-of-issuance-costs https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/proceeds-from-divestiture-of-businesses https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/proceeds-from-divestiture-of-businesses-net-of-cash-divested https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/proceeds-from-issuance-initial-public-offering https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/proceeds-from-issuance-of-preferred-stock-preference-stock-and-warrants https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/proceeds-from-issuance-of-warrants https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/proceeds-from-sale-maturity-and-collections-of-investments https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/proceeds-from-sale-of-intangible-assets https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/proceeds-from-sale-of-property-plant-and-equipment https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/proceeds-from-short-term-debt https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/proceeds-from-stock-issued https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/proceeds-from-stock-options-exercised https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/property-plant-and-equipment-gross https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/property-plant-equipment https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/public-float https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/repayments-of-debt https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/research-and-development https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/restricted-cash-and-cash-equivalents https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/restricted-cash-and-cash-equivalents-at-carrying-value https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/restricted-cash-and-cash-equivalents-noncurrent https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/restructuring-and-related-cost-number-of-positions-eliminated https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/restructuring-charges https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/restructuring-reserve-accelerated-depreciation https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/restructuring-reserve-accrual-adjustment https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/restructuring-reserve-change https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/restructuring-reserve-current https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/restructuring-reserve-settled-with-cash https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/retained-earnings https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/revenue https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/royalty-revenue https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/sale-of-stock-consideration-received-on-transaction https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/sec-comment-letters-corresp https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/sec-comment-letters-upload https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/sec-filings-10-k https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/sec-filings-10-q https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/sec-filings-25-nse https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/sec-filings-425 https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/sec-filings-8-a12g https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/sec-filings-8-k https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/sec-filings-ars https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/sec-filings-ct-order https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/sec-filings-def-14a https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/sec-filings-defa14a https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/sec-filings-pre-14a https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/sec-filings-prer14a https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/sec-filings-regdex https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/sec-filings-revoked https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/sec-filings-s-4 https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/sec-filings-sc-14f1 https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/sec-filings-sc-to-c https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/secondary-offerings-form-424b1 https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/secondary-offerings-form-424b2 https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/secondary-offerings-form-424b3 https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/secondary-offerings-form-424b5 https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/secondary-offerings-form-effect https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/secondary-offerings-form-pos-am https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/secondary-offerings-form-s-1 https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/secondary-offerings-form-s-3 https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/secondary-offerings-form-s-3mef https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/secondary-offerings-form-s-8 https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/settlement-liabilities-current https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/share-price https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/shareholders-equity https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/shares-authorized https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/shares-issued https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/shares-issued-shares-new-issues https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/short-term-borrowings https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/stock-award-award-vesting-rights-percentage https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/stock-award-fair-value-assumptions-risk-free-interest-rate https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/stock-award-fair-value-assumptions-weighted-average-volatility-rate https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/stock-award-number-of-shares-authorized https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/stock-award-options-exercises-in-period-average-exercise-price https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/stock-award-options-forfeitures-in-period-average-exercise-price https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/stock-award-options-grants-in-period-average-exercise-price https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/stock-award-shares-issued-in-period https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/stock-based-compensation https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/stock-issued-new-shares-sold https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/stock-issued-shares-issued-for-options-exercised https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/stock-issued-shares-issued-value-conversion-of-convertible-securities https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/stock-issued-shares-issued-value-other https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/stock-issued-shares-issued-value-restricted-stock-award-net-of-forfeitures https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/stock-issued-shares-issued-value-stock-options-exercised https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/stock-issued-value-of-shares-issued-for-acquisitions https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/stock-issued-value-of-shares-issued-for-stock-awards https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/stock-option-plan-expense https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/stock-options-exercisable-average-exercise-price https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/stock-options-exercisable-intrinsic-value https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/stock-options-exercisable-number https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/stock-options-exercises-in-period-total-intrinsic-value https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/stock-options-forfeitures-and-expirations-in-period https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/stock-options-forfeitures-and-expirations-in-period-average-exercise-price https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/stock-options-forfeitures-in-period https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/stock-options-grants-in-period https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/stock-options-grants-in-period-grant-date-fair-value https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/stock-options-outstanding-average-exercise-price https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/stock-options-outstanding-intrinsic-value https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/stock-options-outstanding-number https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/stock-options-vested-and-expected-to-vest-outstanding-aggregate-intrinsic-value https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/stock-options-vested-and-expected-to-vest-outstanding-average-exercise-price https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/stock-options-vested-and-expected-to-vest-outstanding-number https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/stock-split-ratio https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/tax-rate-reconciliation-at-federal-statutory-income-tax-rate https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/tax-rate-reconciliation-change-in-deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/tax-rate-reconciliation-change-in-enacted-tax-rate https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/tax-rate-reconciliation-nondeductible-expense-share-based-compensation-cost https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/tax-rate-reconciliation-other-adjustments https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/tax-rate-reconciliation-state-and-local-income-taxes https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/tax-rate-reconciliation-tax-credits-research https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/tax-reconciliation-change-in-deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/tax-reconciliation-foreign-income-tax-rate-differential https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/tax-reconciliation-nondeductible-expense-impairment-losses https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/tax-reconciliation-other-adjustments https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/tax-reconciliation-state-and-local-income-taxes https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/tax-reconciliation-tax-credits https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/total-assets https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/total-liabilities https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/total-liabilities-and-equity https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/total-long-term-debt https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/unrealized-gain-loss-on-investments https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/unrecognized-tax-benefits https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/utb-income-tax-penalties-and-interest-accrued https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/utb-income-tax-penalties-and-interest-expense https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/utb-reduction-from-statute-lapse https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/valuation-allowance-deferred-tax-asset-change-in-amount https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/warrants-and-rights-outstanding https://stock.noler.com/us/stock/epirus-biopharmaceuticals-inc/weighted-average-number-of-share-outstanding-basic-and-diluted